



**Nick Karos**  
Chief Executive Officer



**Greg Leavens, CPA, CA**  
Chief Financial Officer



**Dr. Ian Rabb**  
Chief Clinics Officer



**Hirpal Hundial**  
Director of Clinical Services



**Colleen Clandening**  
Director, Operations



**Chief Ian Campbell, MBA**  
Chairman (Independent)



**Dr. Alberto Sola, MD**  
Co-Founder and Director



**Robert Turner, ICD.D, MBA**  
Director (Independent)



**Marilyn Loewen Mauritz, ICD.D, JD**  
Director (Independent)



**David Danziger, CPA, CA**  
Director (Independent)



**Anthony DeCristofaro**  
Director (Independent)

## COMPANY OVERVIEW



To provide improved treatment toward better outcomes for those living with addiction by developing and applying a state-of-the-art, comprehensive and holistic, care model. Universal Ibogaine's goal is to develop and medically introduce ibogaine as a central piece in addiction treatment.

## Key Stats

- Listed on the TSXV October 5, 2021
- \$6M pre-public financing round closed in August 2021
- Pursuing clinical trials in Canada expected to result in an 8-year exclusivity to use ibogaine formulations
- Revenue-generating Kelburn Addiction Recovery Center (Manitoba), along with property consisting of 50 acres of land
- Experienced and proven leadership team, includes extensive experience with ibogaine administration
- Worldwide rights for the Clear Sky Proprietary Treatment and Safety Protocol, and the Clear Sky brand
- Eye toward clinical expansion in Caribbean
- Indigenous strategy for the use of ibogaine to help address the root causes of addiction

# UNIVERSALIBOGAINE Corporate Structure

Totals as at Dec. 31, 2021	Exercise Price	Term	Total # (millions)
Shares issued and outstanding	note 1)		190.6
<b>Shares reserved for issuance:</b>			
Options (Brokers and others)	\$0.10	to Aug 31, 2023	4.8
Options (Directors, Officers, and Key People)	\$0.25	5 years	14.0
Performance shares - CEO and Directors	note 2)	n/a	3.3
Advisors warrants	\$0.25	Dec 31, 2024	9.0
Share Purchase Warrants (5 year term)	note 3)	Aug 31, 2026	51.3
Total Shares reserved	✦		82.4
<b>Fully Diluted Total</b>			<b>273.0</b>

**Notes** 1) Includes 30 million shares issued to Clear Sky, 90% of which will be subject to future performance milestones  
 2) Future releases based on UI achieving performance milestones  
 3) Warrants exercise price of \$0.50 in year 1, escalating by \$0.25 per year to \$1.50 in year 5 (Expiry August 31, 2026)



## Potential Revenue Drivers

Clinics (operation, training, licensing, franchising).

Patient referrals or direct operation in the Caribbean where and when authorized.

Operation on indigenous lands where and when appropriate.

Accelerated medicalization/commercialization of ibogaine post completion of the HPOC/Ph2 study.

Monetization of other addiction medicine / technology, etc.

## The Addiction Crisis

- A death occurs in Canada due to illicit drug overdose every 2 hours\*.
- One in five Canadians live with addiction
- Addiction is closely intertwined with mental/behavioral health and CNS - All subject to an increasing societal and industrial focus.
- Current addiction management, although a good start, is in many cases generally inadequate: recidivism (relapse) rate is >90%\*.
- Addiction is addressed primarily as an acute, singular, condition. There is a strong case for multi-faceted, chronic, disease management approaches.
- Increased reliance on “substitution therapy” in addiction management whereby, for example, another opioid is introduced as a long-term treatment for opioid use disorder.
- “Harm reduction” practices are becoming increasingly popular. However, they don’t blunt addiction or address its underlying causes.

## The Addiction Interrupter:

**Ibogaine is a naturally-occurring molecule derived from the root bark of the iboga tree.**

- Potent and serious medical psychedelic demonstrated to have addiction-interrupting effects.
- Broad spectrum (promiscuous) agonizer: targets multiple receptors across multiple sites in the brain.
- Metabolizes into noribogaine, a serotonin re-uptake inhibitor that remains in the body for 1-4 months, associated with elimination of addictive cravings.
- Included on the Prescription Drug List in Canada (vs. Schedule 1 in the US) facilitating medicalization.



\*Sources: [www.cbc.ca/news/canada/british-columbia/overdose-crisis-bc-public-health-agency-canadareport-1.4902884](http://www.cbc.ca/news/canada/british-columbia/overdose-crisis-bc-public-health-agency-canadareport-1.4902884);

# Why UNIVERSALIBOGAINE?



Offers an opportunity to help tackle the scourge of addiction. We present an ethical, medically supervised and regulatory- sanctioned channel to participate in the PSYCHEDELICS space.



Our ibogaine “biotech” play is partially “de-risked” due to the real-world data/evidence base of safety and efficacy, and the successful track record of our Clear Sky Recovery treatment/safety protocol.



We represent a commercialization and monetization opportunity in a large, severely underserved, therapeutic area



Opportunity to capture biotech upside while growing near-term revenue from expansion of clinics.



Favourable valuation compared with companies in the (psychedelic) space as we are at the ground level, at a pretransformative growth stage.

## Clinical Trials *and* Seeking Approvals

**We are pursuing Health Canada approval to conduct clinical trials to demonstrate the safety and efficacy of ibogaine in treating opioid use disorder.**



The study is intended to ultimately lead to the medical use of ibogaine in Canada, and to support similar endeavours in other G7 countries.



The study will be led by a strong medical team, potentially with institutional support, and will be facilitated by experienced Clinical Research Organizations.




Successful ibogaine development will afford us 8 year data exclusivity protection for innovative medicines in Canada, and opens doors for future drug development and intellectual property generation.

## Plans to Drive Growth

**Innovation in long-term addiction care: ibogaine, works differently and more effectively than current addiction medicines.**

Universal Ibogaine plans to transform addiction management, while developing ibogaine as a central component of the innovation to addiction treatment

1. Develop Addiction Drug (Ibogaine)
2. Acquire existing Addiction Clinics
3. Opportunity to build Caribbean-Based Addiction Management
4. Build Indigenous Holistic Addiction Management




- Pre-CTA Meeting
- CTA Submission
- NOL
- Ph2/HPOC Initiation\*

- Ph2/HPOC Completion
- Ph2/HPOC Readout
- Special Access (or Ph3/pivotal Start)

**DRUG (IBOGAINE) DEVELOPMENT PROGRAM: PROJECTED ROADMAP**

\*Human proof of concept study (usually aligned with a ph28 (phase) development stage)

**MILESTONES**



\*Acronyms: CTA = clinical trial application; MOU = Memorandum of Understanding

**Contact: Dugan Selkirk, IR/PR Manager**  
 Dugan.Selkirk@universalibogaine.com  
<https://calendly.com/ui-investor-relations/welcome>  
[www.universalibogaine.com](http://www.universalibogaine.com) for Full Investor Presentation